Katharina Strobel

Katharina Strobel

Auto-generated profile, based on publicly available information

Katharina Strobel

Department of Dermatology Venereology and Allergology University Hospital Würzburg Würzburg Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2022 in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Verified
Journal Article
Open access
KSKatharina Strobel
Katharina Strobel
CSChristina Sickenberger
Christina Sickenberger
CSChristoph Schoen
Christoph Schoen
HKHermann Kneitz
Hermann Kneitz
AKAnnette Kolb‐Mäurer
Annette Kolb‐Mäurer
MGMatthias Goebeler
Matthias Goebeler
Background and Objectives: In Europe, infections with Mycobacterium (M.) marinum are rare. We conducted a retrospective single-center study to assess the clinical spectrum of M. marinum infection and its diagnosis, treatment and outcome under real-world conditions. Patients and Methods: Eighteen patients presenting with M. marinum infections between 1998 and 2018 were identified in the data warehouse of the University Hospital Wurzburg and considered for detailed analysis. Results: Twelve patients reported aquatic exposure. In 16/18 cases the upper extremities were affected. No invasive infections were detected. Mean time to diagnosis was 15 weeks. Histology revealed granulomatous inflammation in 14 patients while mycobacterial cultures were positive for M. marinum in 16 cases. Most patients received antibiotic monotherapy (14/18) while combination therapy was administered in four cases. Treatment (with a median duration of 10 weeks) was successful in 13 patients. Five patients were lost to follow-up. Conclusions: Our retrospective analysis of M. marinum infections at a German tertiary referral center revealed a considerable diagnostic delay and the relevance of microbiological culture, PCR and histology for diagnosis. Monotherapy with clarithromycin (rather than doxycycline) appeared as a reasonable treatment option while immunosuppressed or -compromised patients and those with extended disease received combination therapy.

3 April 2024 in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Verified
Journal Article
Open access
TDTassilo Dege
Tassilo Dege
INIsabel Netzer
Isabel Netzer
KSKatharina Strobel
Katharina Strobel
MGMatthias Goebeler
Matthias Goebeler
MWMarion Wobser
Marion Wobser

10 June 2024 in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Verified
Journal Article
Open access
TDTassilo Dege
Tassilo Dege
INIsabel Netzer
Isabel Netzer
KSKatharina Strobel
Katharina Strobel
MGMatthias Goebeler
Matthias Goebeler
MWMarion Wobser
Marion Wobser